The economic impact of gout: A systematic literature review

Clinical and Experimental Rheumatology

Volumn 30, Issue 4 SUPPL.73, 2012, Pages

  Trieste, L ^a   Palla, I ^a   Fusco, F ^a   Tani, C ^b   Baldini, C ^b   Mosca, M ^b   Turchetti, G ^a  

^a SCUOLA SUPERIORE SANT ANNA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Adherence to therapy; Costs; Gout; Prevention; Review

Indexed keywords

ALLOPURINOL; ANTIGOUT AGENT; URIC ACID;

ARTICLE; COMORBIDITY; COST OF ILLNESS; DISEASE SEVERITY; DRUG COST; GOUT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

COST OF ILLNESS; COSTS AND COST ANALYSIS; DRUG COSTS; GOUT; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; PATIENT COMPLIANCE; SECONDARY PREVENTION;

EID: 84870286314     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. ROUBENOFF R: Gout and hyperuricemia. Rheum Dis Clin Ther 1990;16:539-50.
2. KIM KY, SCHUMACHER R, HUNSCHE E, WERTHEIMER AL, KONG SX: A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003;25:1593-617.
3. Centre For Reviews And Dissemination, CRD's guidance for undertaking reviews in health care, 2008, University of York.
4. Cochrane Handbook for Systematic Reviews of interventions, HIGGINS J P T, GREEN S (Eds.), 2008, Wiley-Blackwell.
5. BROOK R, KLEINMAN N, PATEL P et al.: The economic burden of gout on an employed population. Curr Med Res Opin 2006;22:1381-9.
6. KLEINMAN N, BROOK R, PATEL P et al.: The impact of gout on work absence and productivity. Value in Health 2007;10:231-7.
7. WU E, PATEL P, YU A et al.: Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm 2008;14:164-75.
8. KHANNA D, AHMED M, YONTZ D, GINSBURG S, TSEVAT J: Willingness to pay for a cure in patients with chronic gout. Med Decis Making 2008;28:606-13.
9. KRISHNAN E, LIENESCH D, KWOH C: Gout in ambulatory care settings in the United States. J Rheumatol 2008;35:498-501.
10. WU E, PATEL P, MODY R et al.: Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol 2009;36:1032-40.
11. HALPERN R, FULDEORE M, MODY R, PATEL P, MIKULS T: The effect of serum urate on gout flares and their associated costs, an administrative claims analysis. J Clin Rheumatol 2009;15:3-7.
12. NITICHAIKULVATANA P, UPCHURCH K, HARROLD L: Impact of deficits in gout care on hospitalizations. J Clin Rheumatol 2011;17:389-91.
13. PARK H, RASCATI K, PRASLA K, TYRONE MCBAY NE: Evaluation of health care costs and utilization patterns for patients with gout. Clin Ther 2012;34:640-52.
14. HANLY J, SKEDGEL C, SKETRIS I et al.: Gout in the elderly - a population health study. J Rheumatol 2009;36:822-30.
15. NOVAK S, MELKONIAN A, PATEL A, KLEINMAN N, JOSEPH-RIDG E, BROOK R: Metabolic syndrome-related conditions among people with and without gout: prevalence and resource use. Curr Med Res Opin 2007;23:623-30.
16. HALPERN R, MODY R, FULDEORE M, PATEL P, MIKULS T: Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis, Curr Med Res Opin 2009;25:1711-9.
17. DALBETH N, PETRIE K, HOUSE M et al.: Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability. Arthritis Care Res 2011;11:1605-12.
18. TANI C, CARLI L, MOSCA M et al.: Adherence to cervical cancer screening in an Italian SLE cohort. Reumatismo 2011;63:11-7.
19. MOSCA M, TANI C, ARINGER M et al.: Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. Autoimmun Rev 2011;10:383-8.
20. CABANA MD, RAND CS, POWE NR et al.: Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999 20;282:1458-65.
21. TURCHETTI G, SPADONI E, GEISLER E: Health technology assessment. Evaluation of biomedical innovative technologies. IEEE Engineering in Medicine and Biology Magazine 2010;29:70-6.
22. TURCHETTI G, SCALONE L, DELLA CASA ALBERIGHI O et al.: The rationale of pharmacoeconomic analysis in rheumatologic indications. Clin Exp Rheumatol 2012;30(Suppl. 73):S64-S71.
23. FURNERI G, MANTOVANI LG, BELISARI A et al.: Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin Exp Rheumatol 2012;30(Suppl. 73):S72-S84.
24. TURCHETTI G, YAZDANY J. PALLA I, YELIN E, MOSCA M. Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider. Clin Exp Rheumatol 2012;30(Suppl. 73):S116-S122.
25. MOSCA M, BOUMPAS D, BRUCE IN et al.: Treat-to-target in systemic lupus erythematosus: where are we today? Clin Exp Rheumatol 2012;30(Suppl. 73):S112-S115.
26. PALLA I, TRIESTE L, TANI C et al.: A systematic literature review of the economic impact of ankylosing spondylitis. Clin Exp Rheumatol 2012;30(Suppl. 73):S136-S141
27. TRIESTE L, PALLA I, BALDINI C et al.: Systemic vasculitis: how little we know about their societal and economic burden. Clin Exp Rheumatol 2012;30(Suppl. 73):S154-S156.
28. CORTESI PA, SCALONE L, D'ANGIOLELLA L et al.: Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis. Clin Exp Rheumatol 2012;30(Suppl. 73):S126-S131.